CIN2

18 registered clinical trials studyying CIN2 — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Empowering Women - Shared Decision Making in Managing Cervical Precancer NCT07146152	University of Aarhus	N/A
Unknown	Performance of Tampons as a Biospecimen Collection Tool for the Detection of Human Papillomavirus in a Colposc NCT06210074	Tampon Innovations Ltd	N/A
Recruiting	Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa NCT05413798	UNC Lineberger Comprehensive Cancer Center	N/A
Completed	Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living NCT05413811	UNC Lineberger Comprehensive Cancer Center	N/A
Terminated	A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Ch NCT05584332	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Recruiting	Regression of Cervical Precancerous Lesions and Associated Risk Factors NCT06147388	General University Hospital, Prague	—
Recruiting	Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine NCT05371353	Shanghai Bovax Biotechnology Co., Ltd.	—
Recruiting	Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years NCT05027776	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Recruiting	Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Year NCT04895020	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females NCT05372016	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Fem NCT04425291	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Recruiting	Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Female NCT04422366	Shanghai Bovax Biotechnology Co., Ltd.	Phase 3
Completed	Conservative Management of CIN2 Lesions and Biomarkers Evaluation NCT04687267	Istituto Oncologico Veneto IRCCS	—
Completed	Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females NCT03676101	Shanghai Bovax Biotechnology Co., Ltd.	Phase 1
Completed	Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Year NCT03177863	Sahlgrenska University Hospital	N/A
Recruiting	Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women. NCT02956031	University of Pretoria	—
Completed	Phase II Evaluation of AHCC for the Eradication of HPV Infections NCT02405533	The University of Texas Health Science Center, Houston	N/A
Unknown	Cervical Cancer Screening With Human Papillomavirus Testing NCT01881659	International Agency for Research on Cancer	—